Loading clinical trials...
Loading clinical trials...
An Open-Label Study to Investigate the Effect of Renal Impairment on the Pharmacokinectics of Tenofovir Exalidex
Conditions
Interventions
Tenofovir Exalidex (TXL)
Locations
1
United States
Orlando Clinical Research Center
Orlando, Florida, United States
Start Date
September 28, 2017
Primary Completion Date
January 17, 2018
Completion Date
February 20, 2018
Last Updated
June 6, 2018
NCT07154901
NCT07165015
NCT06352411
NCT07445906
NCT06661733
NCT07124403
Lead Sponsor
ContraVir Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions